OBJECTIVE: The aim of this study was to estimate the prevalence of menopausal symptoms in relation to treatment modalities in Asian women treated for breast cancer. METHODS: A population-based cohort of 5,023 Chinese women aged 25 to 70 years with primary stage 0 to III breast cancer was identified from a population-based tumor registry and enrolled in the study approximately 6 months after diagnosis. Participants were asked about the occurrence of specific menopausal symptoms. Associations between these symptoms and breast cancer treatments were evaluated by stratified, multivariate logistic regression. RESULTS: Among women with a recent diagnosis of breast cancer, 67.2% of premenopausal women and 46.3% of postmenopausal women experienced at least one menopausal symptom, namely, hot flashes, night sweats, and/or vaginal dryness. Symptom prevalence among postmenopausal women decreased progressively with age at diagnosis (63.3% for women aged 51-55 y, 51.5% for women aged 56-60 y, and 34.4% for women aged >65 y; P < 0.01). Overall, the highest prevalence of most symptoms occurred in women aged 46 to 55 years (P < 0.01). Chemotherapy was positively associated with the occurrence of any symptom and with each individual symptom, mainly in premenopausal women (adjusted odds ratio [OR] range, 2.2-3.3; P < 0.05 for all). Tamoxifen use and immunotherapy were associated with having any symptom and with each individual symptom, regardless of menopause status (adjusted OR range, 1.5-1.8 and 1.3-1.5, respectively; P < 0.05 for all). Women treated before menopause were at particularly high risk of experiencing two or more symptoms after chemotherapy (OR, 1.77; 95% CI, 1.54-4.98; P interaction = 0.05) compared with postmenopausal women. CONCLUSIONS: Menopausal symptoms are prevalent among Chinese women recently treated for primary breast cancer. These symptoms are associated with age and menopause status at the time of diagnosis, as well as with the type of treatment received.
OBJECTIVE: The aim of this study was to estimate the prevalence of menopausal symptoms in relation to treatment modalities in Asian women treated for breast cancer. METHODS: A population-based cohort of 5,023 Chinese women aged 25 to 70 years with primary stage 0 to III breast cancer was identified from a population-based tumor registry and enrolled in the study approximately 6 months after diagnosis. Participants were asked about the occurrence of specific menopausal symptoms. Associations between these symptoms and breast cancer treatments were evaluated by stratified, multivariate logistic regression. RESULTS: Among women with a recent diagnosis of breast cancer, 67.2% of premenopausal women and 46.3% of postmenopausal women experienced at least one menopausal symptom, namely, hot flashes, night sweats, and/or vaginal dryness. Symptom prevalence among postmenopausal women decreased progressively with age at diagnosis (63.3% for women aged 51-55 y, 51.5% for women aged 56-60 y, and 34.4% for women aged >65 y; P < 0.01). Overall, the highest prevalence of most symptoms occurred in women aged 46 to 55 years (P < 0.01). Chemotherapy was positively associated with the occurrence of any symptom and with each individual symptom, mainly in premenopausal women (adjusted odds ratio [OR] range, 2.2-3.3; P < 0.05 for all). Tamoxifen use and immunotherapy were associated with having any symptom and with each individual symptom, regardless of menopause status (adjusted OR range, 1.5-1.8 and 1.3-1.5, respectively; P < 0.05 for all). Women treated before menopause were at particularly high risk of experiencing two or more symptoms after chemotherapy (OR, 1.77; 95% CI, 1.54-4.98; P interaction = 0.05) compared with postmenopausal women. CONCLUSIONS: Menopausal symptoms are prevalent among Chinese women recently treated for primary breast cancer. These symptoms are associated with age and menopause status at the time of diagnosis, as well as with the type of treatment received.
Authors: Ellen B Gold; Alicia Colvin; Nancy Avis; Joyce Bromberger; Gail A Greendale; Lynda Powell; Barbara Sternfeld; Karen Matthews Journal: Am J Public Health Date: 2006-05-30 Impact factor: 9.308
Authors: John F Randolph; MaryFran Sowers; Irina Bondarenko; Ellen B Gold; Gail A Greendale; Joyce T Bromberger; Sarah E Brockwell; Karen A Matthews Journal: J Clin Endocrinol Metab Date: 2005-09-06 Impact factor: 5.958
Authors: Janet S Carpenter; Julie L Elam; Sheila H Ridner; Pam H Carney; Gloria J Cherry; Heather L Cucullu Journal: Oncol Nurs Forum Date: 2004-05 Impact factor: 2.172
Authors: Tsogzolmaa Dorjgochoo; Kai Gu; Ying Zheng; Asha Kallianpur; Zhi Chen; Wei Zheng; Wei Lu; Xiao Ou Shu Journal: Breast Cancer Res Treat Date: 2010-08-12 Impact factor: 4.872
Authors: Katherine E Cameron; Martha B Kole; Mary D Sammel; Jill P Ginsberg; Yasmin Gosiengfiao; Jennifer E Mersereau; H Irene Su; Clarisa R Gracia Journal: Oncology Date: 2018-01-26 Impact factor: 2.935
Authors: Yuan-Yuan Lei; Suzanne C Ho; Ashley Cheng; Carol Kwok; Ka Li Cheung; Yi-Qian He; Roselle Lee; Winnie Yeo Journal: Breast Cancer Res Treat Date: 2020-04-01 Impact factor: 4.872
Authors: Giok S Liem; Frankie K F Mo; Elizabeth Pang; Joyce J S Suen; Nelson L S Tang; Kun M Lee; Claudia H W Yip; Wing H Tam; Rita Ng; Jane Koh; Christopher C H Yip; Grace W S Kong; Winnie Yeo Journal: PLoS One Date: 2015-10-20 Impact factor: 3.240